Increased demands for plasmid DNA (pDNA) for emerging nucleic acid-based vaccines and therapies exacerbate the need to remove bottlenecks from pDNA production. For industry, the problem has been that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results